Roth Capital Expects Weaker Earnings for ARS Pharmaceuticals

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Research analysts at Roth Capital dropped their Q3 2027 earnings per share (EPS) estimates for ARS Pharmaceuticals in a research report issued on Monday, November 10th. Roth Capital analyst K. Bauser now forecasts that the company will earn $0.32 per share for the quarter, down from their previous forecast of $0.41. Roth Capital currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.55) per share.

ARS Pharmaceuticals (NASDAQ:SPRY) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.07). The firm had revenue of $32.50 million during the quarter, compared to the consensus estimate of $28.87 million. ARS Pharmaceuticals had a negative net margin of 56.06% and a negative return on equity of 38.77%.

Other research analysts have also recently issued research reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ARS Pharmaceuticals in a report on Wednesday, October 8th. Zacks Research lowered ARS Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 22nd. Raymond James Financial set a $32.00 price target on ARS Pharmaceuticals in a report on Friday, September 26th. Finally, Wall Street Zen lowered ARS Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, July 26th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $31.80.

ARS Pharmaceuticals Stock Performance

NASDAQ SPRY opened at $8.94 on Wednesday. The company’s 50 day simple moving average is $9.83 and its two-hundred day simple moving average is $13.46. The company has a debt-to-equity ratio of 1.14, a current ratio of 6.66 and a quick ratio of 5.98. ARS Pharmaceuticals has a 1 year low of $8.05 and a 1 year high of $18.90. The stock has a market capitalization of $883.72 million, a PE ratio of -11.04 and a beta of 0.83.

Institutional Investors Weigh In On ARS Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp grew its position in ARS Pharmaceuticals by 1.5% during the 1st quarter. Bank of New York Mellon Corp now owns 132,213 shares of the company’s stock worth $1,663,000 after acquiring an additional 1,975 shares during the last quarter. FAS Wealth Partners Inc. boosted its stake in shares of ARS Pharmaceuticals by 47.3% during the first quarter. FAS Wealth Partners Inc. now owns 139,535 shares of the company’s stock valued at $1,755,000 after purchasing an additional 44,830 shares during the period. Legato Capital Management LLC grew its holdings in shares of ARS Pharmaceuticals by 350.1% in the first quarter. Legato Capital Management LLC now owns 96,591 shares of the company’s stock worth $1,215,000 after purchasing an additional 75,130 shares during the last quarter. ANTIPODES PARTNERS Ltd purchased a new position in shares of ARS Pharmaceuticals in the first quarter worth $37,000. Finally, Knights of Columbus Asset Advisors LLC purchased a new position in shares of ARS Pharmaceuticals in the first quarter worth $543,000. 68.16% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at ARS Pharmaceuticals

In other news, CEO Richard E. Lowenthal sold 50,000 shares of the company’s stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $14.49, for a total value of $724,500.00. Following the completion of the sale, the chief executive officer owned 1,196,494 shares of the company’s stock, valued at approximately $17,337,198.06. This represents a 4.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Kathleen D. Scott sold 12,500 shares of the stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $15.00, for a total transaction of $187,500.00. Following the transaction, the chief financial officer directly owned 10,042 shares in the company, valued at approximately $150,630. This represents a 55.45% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 112,500 shares of company stock worth $1,615,759. 33.50% of the stock is currently owned by insiders.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.